Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALC 
Alcon AG (ALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ALC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
27 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $105.26
Year Target Price $105.26
| 15 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.01% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 43.44B USD | Price to earnings Ratio 39.03 | 1Y Target Price 105.79 |
Price to earnings Ratio 39.03 | 1Y Target Price 105.79 | ||
Volume (30-day avg) - | Beta 0.7 | 52 Weeks Range 80.19 - 100.74 | Updated Date 06/29/2025 |
52 Weeks Range 80.19 - 100.74 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.38% | Basic EPS (TTM) 2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.28% | Operating Margin (TTM) 13.3% |
Management Effectiveness
Return on Assets (TTM) 2.74% | Return on Equity (TTM) 5.23% |
Valuation
Trailing PE 39.03 | Forward PE 27.93 | Enterprise Value 47233888238 | Price to Sales(TTM) 4.38 |
Enterprise Value 47233888238 | Price to Sales(TTM) 4.38 | ||
Enterprise Value to Revenue 4.76 | Enterprise Value to EBITDA 30.85 | Shares Outstanding 494616000 | Shares Floating 494599546 |
Shares Outstanding 494616000 | Shares Floating 494599546 | ||
Percent Insiders 0.13 | Percent Institutions 67.77 |
Analyst Ratings
Rating 4.33 | Target Price 105.26 | Buy 6 | Strong Buy 15 |
Buy 6 | Strong Buy 15 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alcon AG
Company Overview
History and Background
Alcon was founded in 1945 in Fort Worth, Texas. Originally a small pharmacy, it grew into a global leader in eye care. Nestlu00e9 acquired Alcon in 1978. Novartis acquired Alcon from Nestlu00e9 in stages, completing the acquisition in 2011. In 2019, Alcon spun off from Novartis to become an independent, publicly traded company.
Core Business Areas
- Surgical: Focuses on products for cataract, refractive, vitreoretinal surgery, and advanced technology intraocular lenses (IOLs).
- Vision Care: Offers contact lenses, lens care products, and over-the-counter eye drops.
Leadership and Structure
David J. Endicott serves as the Chief Executive Officer. The company operates with a global organizational structure, dividing operations into the Surgical and Vision Care segments, with regional management teams overseeing sales and distribution in different geographic areas.
Top Products and Market Share
Key Offerings
- PanOptix IOL: A trifocal intraocular lens for cataract surgery. Competitors include Johnson & Johnson Vision (JNJ) and Bausch + Lomb (BLCO). While specific market share data fluctuates, PanOptix is a leading product in the advanced IOL segment. Revenue from this product is not publicly broken out.
- Dailies Total1 Contact Lenses: Daily disposable contact lenses. Competitors include Johnson & Johnson Vision (JNJ), CooperVision (COO), and Bausch + Lomb (BLCO). Dailies Total1 is a premium brand with a significant share in the daily disposable market. Market share is not publicly broken out, but this product line is a large revenue driver.
- Systane Lubricant Eye Drops: Over-the-counter eye drops for dry eye relief. Competitors include Allergan (ABBV), Bausch + Lomb (BLCO), and Similasan. Systane is a leading brand in the artificial tears market, holding a substantial market share, although exact figures are not readily available. Revenue data is not specifically broken out.
Market Dynamics
Industry Overview
The eye care industry is growing, driven by aging populations, increased prevalence of eye diseases, and technological advancements in surgical and vision care products. The market is competitive, with several large players and smaller specialized companies.
Positioning
Alcon AG is a leading global eye care company with a strong presence in both surgical and vision care segments. Its competitive advantages include a broad product portfolio, a strong brand reputation, and a global distribution network.
Total Addressable Market (TAM)
The global eye care market is estimated to be over $40 billion. Alcon is well-positioned to capture a significant portion of this market with its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Global brand recognition
- Extensive product portfolio
- Strong R&D capabilities
- Established distribution network
- Leading position in key market segments
Weaknesses
- Dependence on innovation
- Exposure to currency fluctuations
- Competition from generics and biosimilars
- Pricing pressure
Opportunities
- Aging global population
- Growing demand for advanced eye care technologies
- Expansion into emerging markets
- Strategic acquisitions and partnerships
- Growth in specialty IOL market
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Technological disruptions
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- JNJ
- BLCO
- COO
Competitive Landscape
Alcon AG has a strong competitive position due to its broad product portfolio, global presence, and established brand. However, it faces intense competition from other major players in the eye care industry.
Major Acquisitions
Ivantis, Inc.
- Year: 2022
- Acquisition Price (USD millions): 475
- Strategic Rationale: Acquisition added Hydrus Microstent for minimally invasive glaucoma surgery (MIGS) to Alcon's glaucoma portfolio.
Growth Trajectory and Initiatives
Historical Growth: Alcon's historical growth has been driven by new product launches, acquisitions, and expansion into new markets.
Future Projections: Future growth projections depend on analyst estimates and company guidance. Data from market reports provide insights into Alcon's future growth trajectory.
Recent Initiatives: Recent strategic initiatives include investments in R&D, expansion of the product portfolio, and strategic partnerships.
Summary
Alcon is a leading eye care company with a strong global presence and a diverse product portfolio. It benefits from an aging population and increasing demand for eye care solutions. Competition remains intense, and Alcon must continue to innovate. The company must manage pricing pressures effectively while expanding into emerging markets to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alcon AG Investor Relations
- Market Research Reports
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and company information are subject to change. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com | ||
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.